Hitomi Sakai

10PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 12, 2026
Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.

|Apr 10, 2026
BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).

Hitomi Sakai, Rika Kusumoto-Matsuo, Mari Hosonaga

|Mar 26, 2026
Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).

Rurina Watanuki, Hitomi Sakai, Yuri Kimura

|Apr 10, 2025
Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B).

Rurina Watanuki, Hitomi Sakai, Yuri Takehara

|Feb 05, 2025
Awareness and attitude toward cardio-oncology among Japanese gynecologic oncologists in managing patients with endometrial cancer: The Japanese Gynecologic Oncology Group (JGOG) questionnaire surveys.

Yoichi Kobayashi, Mikiko Asai-Sato, Shiho Kuji

|Jan 29, 2025
Management of nausea and vomiting induced by antibody-drug conjugates.

Jawhara Farhat, Hitomi Sakai, Junji Tsurutani

Pageof 2

Frequent Collaborators

2 joint publications

Mikiko Asai-Sato

2 joint publications

Nao Suzuki

2 joint publications

Yoshio Yoshida

2 joint publications

Toshimi Takano